[New therapeutic approaches for the treatment of primary biliary cholangitis].

Primary biliary cholangitis (PBC) is a rare disease for which management long consisted of a single treatment: ursodeoxycholic acid. In 2015-2016, this disease regained interest with the first studies on obeticholic acid (FXR agonist) and then on bezafibrate (PPAR agonist). Subsequently, over the past five years, significant progress has been made in the management of PBC. Major studies have helped better predict disease progression and its response to treatment through the development of prognostic tools. Additionally, the therapeutic arsenal has expanded with the arrival of selective PPAR agonists.